mezagitamab

Key facts

Mechanism of action

Lymphocyte differentiation antigen CD38 binding agent

Primary target: ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1

Approval history

1. Mezagitamab Phase 3 · Takeda · Immune Thrombocytopenic Purpura (ITP)
2. Mezagitamab Phase 3 · Takeda · Chronic Primary Immune Thrombocytopenia
3. Mezagitamab, Placebo matching for Mezagitamab Phase 3 · Takeda · Chronic Primary Immune Thrombocytopenia
4. TAK-079-3001 Phase 3 · Takeda · IgAN is Primary Immunoglobulin A Nephropathy (IgAN) (also kn
5. Mezagitamab Phase 2 · Takeda · Relapsed/Refractory
6. Mezagitamab Phase 1 · Takeda · Kidney Disease
7. TAK-079-1006 Phase 1 · Takeda · IgAN is Primary Immunoglobulin A Nephropathy (IgAN) (also kn

1. daratumumab Antineoplastic and immunomodulating agents (L01)
2. isatuximab-irfc Lymphocyte differentiation antigen CD38 inhibitor
3. isatuximab Antineoplastic and immunomodulating agents (L01)

Frequently asked questions